Literature DB >> 15723238

Molecular imaging system for possible prediction of active retinopathy in patients with Diabetes mellitus.

O Golubnitschaja1, A Jaksche, H Moenkemann, K Yeghiazaryan, S E Karl, D Trog, H H Schild, K U Löffler.   

Abstract

OBJECTIVE: The deposition of advanced glycation end products is enhanced in Diabetes mellitus (DM) and has been linked to diabetic complications such as a microvascular disease. Glycated proteins have receptors on mononuclear blood cells (MBCs) and have been shown to generate reactive oxygen species altering gene expression and modifying cellular targets, such as endothelial cells. Retinal angiopathy is a frequently observed microvascular complication in DM-patients. Because of the central role of activated MBCs, we hypothesised a functional link between specific alterations in gene expression of MBCs, an increased activity of matrix proteases in serum, and the extent of retinal angiopathy in DM.
MATERIAL AND METHODS: An appearance and proliferation index of diabetic retinopathy was evaluated in 38 DM-patients using fluorescein angiography. Alterations of gene transcription levels in MBCs were investigated using hybridisation of individual mRNA-pools to Atlas Array with a concomitant quantification of specific cDNAs by "Real-Time"-PCR. The activity of matrix metalloproteinases MMP-2 and MMP-9 in individual serum samples was measured by zymography combined with densitometric imaging system. RESULTS AND
CONCLUSIONS: Hybridisation to Atlas Array of mRNA-pools isolated from MBCs revealed an enhanced expression of recoverin in DM-patients compared to the control group. "Real-Time"-PCR showed the highest recoverin levels in the DM-subgroup with a high proliferation index. MMP-2 activity was highly increased in 36% of all patients, and in 44, 44, and 19% of patients with proliferative retinopathy, advanced proliferative retinopathy, and no detectable proliferation respectively. In those 3 groups MMP-9 activity was highly increased in 56, 67, and 31% of patients respectively, and in 44% of all DM-patients. In contrast to patients with active proliferation, the simultaneous high activation of all three genes was not observed in patients without active proliferation. The ex vivo molecular imaging system developed in this work may be helpful for the prediction of active proliferative retinopathy in DM.

Entities:  

Mesh:

Year:  2005        PMID: 15723238     DOI: 10.1007/s00726-005-0173-1

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  5 in total

1.  Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers.

Authors:  Mohamed Al-Shabrawey; Sylvia Smith
Journal:  EPMA J       Date:  2010-03-23       Impact factor: 6.543

2.  Opinion controversy to chromium picolinate therapy's safety and efficacy: ignoring 'anecdotes' of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan
Journal:  EPMA J       Date:  2012-10-07       Impact factor: 6.543

3.  Characteristics of inflammation common to both diabetes and periodontitis: are predictive diagnosis and targeted preventive measures possible?

Authors:  Philip J Hanes; Ranjitha Krishna
Journal:  EPMA J       Date:  2010-04-03       Impact factor: 6.543

4.  Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy.

Authors:  Michal Beránek; Petr Kolar; Svatava Tschoplova; Katerina Kankova; Anna Vasku
Journal:  Mol Vis       Date:  2008-06-14       Impact factor: 2.367

5.  Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care.

Authors:  Olga Golubnitschaja; Ian D Watson; Elizabeta Topic; Sverre Sandberg; Maurizio Ferrari; Vincenzo Costigliola
Journal:  EPMA J       Date:  2013-05-10       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.